Charles River Laboratories International, Inc. (CRL) Stake Maintained by Teacher Retirement System of Texas

Teacher Retirement System of Texas continued to hold its stake in Charles River Laboratories International, Inc. (NYSE:CRL) during the first quarter, Holdings Channel reports. The firm owned 3,786 shares of the medical research company’s stock at the end of the first quarter. Teacher Retirement System of Texas’ holdings in Charles River Laboratories International were worth $341,000 as of its most recent SEC filing.

Other hedge funds have also recently added to or reduced their stakes in the company. FMR LLC increased its stake in Charles River Laboratories International by 39.7% in the first quarter. FMR LLC now owns 2,488,113 shares of the medical research company’s stock valued at $223,806,000 after buying an additional 707,612 shares during the period. Ariel Investments LLC increased its stake in Charles River Laboratories International by 30.7% in the first quarter. Ariel Investments LLC now owns 2,060,420 shares of the medical research company’s stock valued at $185,335,000 after buying an additional 483,564 shares during the period. Acadian Asset Management LLC increased its stake in Charles River Laboratories International by 12.1% in the first quarter. Acadian Asset Management LLC now owns 901,154 shares of the medical research company’s stock valued at $81,058,000 after buying an additional 97,344 shares during the period. Neuberger Berman Group LLC increased its stake in Charles River Laboratories International by 0.7% in the first quarter. Neuberger Berman Group LLC now owns 876,633 shares of the medical research company’s stock valued at $78,853,000 after buying an additional 6,148 shares during the period. Finally, Norges Bank purchased a new stake in Charles River Laboratories International during the fourth quarter valued at about $53,008,000. Institutional investors and hedge funds own 98.06% of the company’s stock.

Institutional Ownership by Quarter for Charles River Laboratories International (NYSE:CRL)

Charles River Laboratories International, Inc. (NYSE CRL) traded up 1.00% during mid-day trading on Thursday, hitting $100.45. The stock had a trading volume of 138,417 shares. The company has a market cap of $4.79 billion, a price-to-earnings ratio of 29.40 and a beta of 1.00. Charles River Laboratories International, Inc. has a 12 month low of $67.20 and a 12 month high of $100.66. The firm’s 50-day moving average is $92.20 and its 200 day moving average is $85.91.

Charles River Laboratories International (NYSE:CRL) last posted its quarterly earnings results on Wednesday, May 10th. The medical research company reported $1.29 EPS for the quarter, topping the Zacks’ consensus estimate of $1.14 by $0.15. Charles River Laboratories International had a return on equity of 27.46% and a net margin of 9.28%. The firm had revenue of $445.80 million during the quarter, compared to analyst estimates of $437.04 million. During the same period last year, the company earned $0.98 earnings per share. The business’s revenue for the quarter was up 25.6% on a year-over-year basis. Equities analysts anticipate that Charles River Laboratories International, Inc. will post $5.10 EPS for the current fiscal year.

COPYRIGHT VIOLATION NOTICE: “Charles River Laboratories International, Inc. (CRL) Stake Maintained by Teacher Retirement System of Texas” was first reported by Mideast Time and is the sole property of of Mideast Time. If you are reading this story on another publication, it was copied illegally and reposted in violation of U.S. and international trademark and copyright law. The original version of this story can be read at https://www.mideasttime.com/charles-river-laboratories-international-inc-crl-stake-maintained-by-teacher-retirement-system-of-texas/1802114.html.

CRL has been the subject of several recent research reports. Jefferies Group LLC restated a “buy” rating and issued a $106.00 price target on shares of Charles River Laboratories International in a research note on Friday, April 21st. Citigroup Inc. reiterated a “neutral” rating and set a $104.00 target price (up from $90.00) on shares of Charles River Laboratories International in a research report on Thursday, May 11th. BidaskClub upgraded Charles River Laboratories International from a “buy” rating to a “strong-buy” rating in a research report on Tuesday. Credit Suisse Group reiterated a “neutral” rating and set a $95.00 target price (up from $89.00) on shares of Charles River Laboratories International in a research report on Tuesday, June 6th. Finally, Barclays PLC set a $90.00 target price on Charles River Laboratories International and gave the company a “hold” rating in a research report on Saturday, May 13th. Five investment analysts have rated the stock with a hold rating, three have issued a buy rating and one has assigned a strong buy rating to the stock. The company presently has a consensus rating of “Buy” and a consensus price target of $90.81.

In related news, insider David Ross Smith sold 945 shares of Charles River Laboratories International stock in a transaction on Thursday, June 8th. The stock was sold at an average price of $95.00, for a total transaction of $89,775.00. Following the completion of the sale, the insider now owns 14,203 shares of the company’s stock, valued at $1,349,285. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. Also, insider Davide Molho sold 10,976 shares of Charles River Laboratories International stock in a transaction on Friday, May 26th. The shares were sold at an average price of $92.84, for a total value of $1,019,011.84. Following the sale, the insider now directly owns 27,525 shares of the company’s stock, valued at approximately $2,555,421. The disclosure for this sale can be found here. Insiders sold 13,051 shares of company stock valued at $1,208,566 over the last ninety days. Corporate insiders own 2.20% of the company’s stock.

About Charles River Laboratories International

Charles River Laboratories International, Inc is an early-stage contract research company. The Company is engaged in laboratory animal medicine and science (research model technologies) and develop a portfolio of discovery and safety assessment services, both good laboratory practice (GLP) and non-GLP, which supports its clients from target identification through non-clinical development.

Want to see what other hedge funds are holding CRL? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Charles River Laboratories International, Inc. (NYSE:CRL).

Receive News & Ratings for Charles River Laboratories International Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Charles River Laboratories International Inc. and related companies with MarketBeat.com's FREE daily email newsletter.



Leave a Reply

 
© 2006-2017 Mideast Time.